Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$30.68 - $40.09 $18,776 - $24,535
612 Added 145.71%
1,032 $31,000
Q2 2023

Aug 14, 2023

SELL
$36.12 - $47.5 $17.3 Million - $22.7 Million
-478,796 Reduced 99.91%
420 $16,000
Q1 2023

May 15, 2023

BUY
$35.53 - $43.38 $17 Million - $20.8 Million
479,216 New
479,216 $19.6 Million
Q1 2020

May 15, 2020

SELL
$28.4 - $50.7 $873,129 - $1.56 Million
-30,744 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$36.31 - $46.83 $10.9 Million - $14.1 Million
-300,035 Reduced 90.71%
30,744 $1.39 Million
Q3 2019

Nov 15, 2019

SELL
$35.66 - $44.99 $29.7 Million - $37.5 Million
-833,862 Reduced 71.6%
330,779 $12.6 Million
Q2 2019

Aug 14, 2019

BUY
$36.57 - $47.97 $19.4 Million - $25.5 Million
531,059 Added 83.82%
1,164,641 $50.7 Million
Q1 2019

May 15, 2019

BUY
$36.47 - $42.17 $875,899 - $1.01 Million
24,017 Added 3.94%
633,582 $24.1 Million
Q4 2018

Feb 14, 2019

BUY
$41.31 - $52.16 $15.3 Million - $19.4 Million
371,169 Added 155.69%
609,565 $26.2 Million
Q3 2018

Nov 14, 2018

BUY
$32.85 - $52.0 $4.49 Million - $7.11 Million
136,760 Added 134.56%
238,396 $11.7 Million
Q2 2018

Aug 14, 2018

BUY
$27.5 - $39.8 $2.47 Million - $3.58 Million
89,936 Added 768.68%
101,636 $3.26 Million
Q1 2018

May 15, 2018

SELL
$29.98 - $46.35 $14.7 Million - $22.7 Million
-489,300 Reduced 97.66%
11,700 $364,000
Q4 2017

Feb 14, 2018

SELL
$31.85 - $46.95 $18.6 Million - $27.4 Million
-583,886 Reduced 53.82%
501,000 $22.9 Million
Q3 2017

Nov 14, 2017

BUY
$35.7 - $39.5 $38.7 Million - $42.9 Million
1,084,886
1,084,886 $40.7 Million

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $1.18B
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track Steven Cohen's Portfolio

Track Steven Cohen Portfolio

Follow Steven Cohen (Point72 Asset Management, L.P.) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.